Funded Biotechnology Startups in La Jolla
Across the 18 most recent biotech funding rounds in La Jolla shown here, the largest disclosed amount is Janux Therapeutics at $350M on 2024-12-03.
Across the 18 most recent biotech funding rounds in La Jolla shown here, the largest disclosed amount is Janux Therapeutics at $350M on 2024-12-03. That $350M round dwarfs every other disclosed entry: the next-largest disclosed amounts are $150M (Inhibrx on 2025-01-13 and Kura Oncology on 2024-01-24), followed by $100M (Boundless Bio on 2023-05-16) and $85M (Rampart Bioscience on 2023-10-24), placing most rounds well below the top tier.
The list also clusters temporally, with multiple major closes concentrated in 2023–2024: for example, seven rounds from 2023-04-14 through 2023-11-01 include Epic Sciences ($24M), Singlera Genomics ($45M), and Genome Insight ($23M). Stage labels are sparse: 16 of 18 rows show “Series Unknown,” and one additional row is explicitly “undisclosed” (Tentarix Biotherapeutics on 2023-08-15). Disclosed amounts span from a low of $900K (Dare Bioscience on 2020-09-21) to the $350M outlier in late 2024, covering rounds from 2020-09-21 through the most recent 2026-03-27 (Artelo Biosciences, $11M).
Most recent rounds
18 shownRelated listings
Frequently asked
What’s the largest disclosed round in this La Jolla biotech set, and how extreme is it versus the rest?
Janux Therapeutics raised $350M on 2024-12-03, and no other disclosed amount comes close: the next-largest disclosed rounds are $150M each (Inhibrx on 2025-01-13 and Kura Oncology on 2024-01-24). Most other disclosed entries sit between about $3M and $100M (for example, MatriSys Bioscience at $3M on 2021-03-11 and Boundless Bio at $100M on 2023-05-16).
Are rounds clustered in a specific time window in these 18 rows?
Yes. 2023–2024 contains a dense stretch of closes (e.g., Epic Sciences on 2023-04-14, Singlera Genomics on 2022-06-08 aside, and especially 2023-10-24 through 2023-11-01 with Rampart Bioscience at $85M on 2023-10-24 and Genome Insight at $23M on 2023-11-01). The list spans 2020-09-21 (Dare Bioscience, $900K) to 2026-03-27 (Artelo Biosciences, $11M), but the largest-ticket rounds are concentrated in 2024–2025 (Janux $350M in 2024, Inhibrx $150M in 2025).
How dominant is “Series Unknown” in this dataset, and does it affect comparisons across stages?
Stage classification is heavily skewed toward “Series Unknown”: 16 of 18 rows are labeled “Series Unknown,” and one row is explicitly “undisclosed” (Tentarix Biotherapeutics on 2023-08-15). Only two rows show specific series labels: e.g., Genome Insight as Series B ($23M, 2023-11-01) and Boundless Bio as Series C ($100M, 2023-05-16), limiting stage-by-stage contrast.
Which disclosed amount sits at the low end, and is it an isolated datapoint or part of a broader lower band?
The smallest disclosed amount is Dare Bioscience at $900K on 2020-09-21. Other low-to-mid disclosed rounds include MatriSys Bioscience at $3M on 2021-03-11 and Artelo Biosciences at $11M on 2026-03-27, suggesting a lower band exists, but the magnitude gap versus the $350M Janux round remains a clear outlier.
Are there notable outliers besides the top of the range?
Beyond Janux Therapeutics’ $350M (2024-12-03), the other high-end disclosed rounds are $150M (Inhibrx on 2025-01-13; Kura Oncology on 2024-01-24). At the other extreme, Dare Bioscience’s $900K on 2020-09-21 is a pronounced small-round outlier compared with the mid-sized disclosed entries like Epic Sciences at $24M (2023-04-14) and Genome Insight at $23M (2023-11-01).
How does the most recent funding date compare to earlier entries in size and classification?
The most recent row is Artelo Biosciences on 2026-03-27 with a disclosed $11M, labeled “Series Unknown.” Compared with earlier peak-disclosed entries such as Janux Therapeutics at $350M (2024-12-03) and Inhibrx at $150M (2025-01-13), the 2026-03-27 amount falls well below the top tier.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.